Class summary at a glance.

Every drug in the Aromatic Amino Acid Decarboxylation Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $10.3Mcombined across class
Total Rx claims: 35K10K unique beneficiaries
Generic mfrs (active): 18across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Carbidopa

Brand: Lodosyn · 35K Part D claims (CY24) · 10K beneficiaries · First FDA approval: 2010-04-13

5 generic mfrs 0 plans require PA

Low NADAC$0.680

→

Avg plan cost$0.680

Part D spend $10.3M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Carbidopa Levodopa

Brand: Dhivy · — Part D claims (CY24) · First FDA approval: 2022-07-13

13 generic mfrs

Low NADAC$3.61

→

Avg plan cost$3.61

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Carbidopa Tablets

Brand: Carbidopa · — Part D claims (CY24) · First FDA approval: 2014-04-04

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.